Publication: Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance
Authors
Surowiak, P. ; Matkowski, R. ; Materna, V. ; Györffy, B. ; Wojnar, A. ; Dziegiel, Piotr ; Kornafel, Jan ; Zabel, M.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
Pudelko, Marek
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Elevated expression of the low molecular
weight metallothionein (MT) proteins can be found
typically in breast cancer cases with less favourable
prognosis. The MT gene has been described to be
potentially down-regulated by estrogen receptor alpha.
The present study is aimed at examining the predictive
value of MT expression for results of tamoxifen
treatment in breast cancer in relation to steroid receptor
status. Sixty patients with primary invasive ductal breast
cancers with post-operative tamoxifen treatment were
enrolled in the study. In paraffin sections of the studied
tumours immmunohistochemical reactions were
performed using antibodies directed against MT,
estrogen receptors (ER) and progesterone receptors
(PgR). Results of the immunohistochemical reactions
and of clinical observations were analysed using
multivariate progression analysis based on the Cox
proportional hazard model. Elevated MT expression was
demonstrated to be typical for cases with documented
relapse of the disease (P<0.001) or terminated by death
(P=0.03). Decreased ER expression was found to be
typical for cases of a higher grade (P=0.02) and cases
terminated by death (P=0.006). The multivariate
analysis showed that elevated MT expression was characteristic for cases with shorter overall survival time
(P=0.04). The data showed that MT carried an
independent, and also independent from ER status,
unfavourable predictive value as far as results of
tamoxifen treatment were concerned.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.